AstraZeneca plans US$50b US move amid tariff threat
The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement.
It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines.
On Monday, AstraZeneca said the expansion supports its ambition to reach US$80 billion in annual revenue by 2030, with half coming from the US.
The US accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market – the world's largest, worth US$635 billion – before Trump's return to office. The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes.
Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay.
CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The US cannot build or carry the cost of R&D for the entire world,' he said.
US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs.
'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect.
The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place.
The pledge is in addition to the US$3.5 billion in investments the company announced in November 2024, the statement said.
The US$50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson , Novartis, and Sanofi.
Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies.
The new Virginia facility – the company's largest single manufacturing investment – will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said.
The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000. – Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
2 hours ago
- New Straits Times
Brexit's parallels with Trump tariffs tell a tale
In figuring out why the United States tariff shock hasn't sent the economy or financial world into a tailspin, Britain's exit from the European Union trade bloc provides something of a playbook — and without a particularly happy ending. Aside from vast differences in economic scale and global reach, the two episodes bear some comparison in how they upended years of deeply integrated free trade and possibly in how business, the economy at large and financial markets reacted. The 2016 Brexit referendum and Trump's tariffs this year were each widely billed as economic shocks that would send the financial world into paroxysms. They didn't, at least not at the outset. To be sure, both were followed by dramatic downward lurches in the two countries' currencies. But, to some extent, the steep drop in sterling after the referendum vote and the dollar's plunge on President Donald Trump's tariff plan this year helped offset some of the wider impact, at least on stock markets that are loaded with global firms with outsized foreign revenue. More broadly, however, the difficulty in isolating their immediate net impact means no "big bang" economic crisis unfolds to prove critics right, even if their enduring legacy turns out to be a slow burn of economic potential and lost output, often obscured by multiple other crosswinds. In Britain's case, the seismic effects of the Covid-19 pandemic distorted any attempt to easily assess Brexit when it actually happened. Tortuous negotiations with the EU meant the UK's departure eventually occurred on the eve of the health crisis in 2020 and the new trade rules did not come into force until a year later. But in the four years between the referendum surprise and the pandemic, the UK economy never entered a recession nor recorded a negative quarterly GDP print — confounding pro-EU supporters at the time and bolstering the Brexit lobby. Emerging from the twin hits, however, the economy has almost flatlined since. What's more, it's taken more than eight years for the pound's effective exchange rate to recover its pre-referendum levels. Few mainstream economists now doubt that Brexit has taken a serious toll on the UK economy. One academic study by a number of Bank of England economists earlier this year concluded that uncertainty following the referendum resulted in little change in goods exports and imports before the exit was finalised. But after the new rules hit, UK imports fell three per cent and overall exports fell 6.4 per cent, largely because of the 13 per cent hit in exports to the EU. While this slump seems relatively modest compared with the official forecasts of the longer-term hit, the pain has been borne disproportionately by small businesses. And the cumulative damage to London and the service sector over the next 10 years continues to worry the City. The US tariff story is of a completely different order, of course, as it will reverberate across the world economy. But there are some parallels, not least in certain aspects of the market reactions and the initial resilience. Economists estimate that the tariffs could lop anywhere from 0.5 per cent to one per cent off US gross domestic product over time. That's a US$150 billion to US$300 billion hit, which, though painful, would not be an instant crisis for an economy that's growing at a roughly two per cent annualised rate, where imported goods represent just 11 per cent of GDP and where tech and AI trends are generating considerable tailwinds. But as former White House economic adviser Jason Furman said in a New York Times essay last week, the tariff damage is likely not a one-off hit. The loss of 0.5 per cent of GDP, he argued, is "the equivalent of every household in America taking around US$1,000 and lighting it on fire, then doing it again every year. Forever." In the end, the main point of the British comparison is to show how extreme partisan arguments on the pros or cons of such giant economic policy changes don't necessarily get resolved cleanly in adaptive, hardy and hyper-complex economies. The latest YouGov opinion poll shows 56 per cent of Britons now think it was wrong to leave the EU, some nine years after their narrow vote to leave. The jury on Trump's tariffs is still out.
The Star
2 hours ago
- The Star
Zelenskiy says he discussed Russia sanctions, drone deal with Trump
U.S. President Donald Trump meets with Ukrainian President Volodymyr Zelenskiy at the White House in Washington, D.C., U.S., February 28, 2025. REUTERS/Brian Snyder/File Photo
The Sun
3 hours ago
- The Sun
Russia hints at deploying mid-range missiles after ending INF moratorium
MOSCOW: Russia on Tuesday suggested it could deploy intermediate-range missiles after ending a self-imposed moratorium on producing or deploying the weapons, which were banned for decades under a Cold War treaty with the United States. Washington and Moscow had prohibited missiles with a range of 500 to 5,500 kilometres (300-3,400 miles) under the 1987 Intermediate-Range Nuclear Forces (INF) Treaty. But US President Donald Trump withdrew from the deal during his first term in 2019, accusing Russia of failing to comply. The Kremlin said at the time it would continue to abide by a moratorium if the United States did not deploy missiles within striking distance of Russia. Russia's foreign ministry said Monday it was ending the self-imposed restrictions, with the Kremlin hinting on Tuesday that Moscow could soon deploy the previously-banned missiles. 'There are no longer any restrictions in Russia in this regard. Russia no longer considers itself limited in any way,' President Vladimir Putin's spokesman, Dmitry Peskov, told reporters. Moscow was 'entitled, if necessary, to take appropriate measures' on the deployment of the missiles, he said, adding that there would be no public announcement if Russia decided to station the missiles. Putin said last year Russia should start producing mid-range missiles -- capable of carrying nuclear warheads -- after the United States sent some launch systems to Denmark for training exercises. Russia has also accused the United States of sending the systems to the Philippines and Australia for drills. 'The United States and its allies have not only openly outlined plans to deploy American land-based INF missiles in various regions, but have also already made significant progress in the practical implementation of their intentions,' Russia's foreign ministry said in a statement. The move comes after Trump announced the deployment of two nuclear submarines 'in the region' amid an online row with Dmitry Medvedev, Russia's former president. Medvedev on Monday said Russia's foes should be on standby. 'This is a new reality all our opponents will have to reckon with. Expect further steps,' he said in his first social media post since the row with Trump erupted. - AFP
